Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections

Kura Oncology, Inc.

2023-Q1 EPS reported -$0.50

Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.
Phase 2 registration trial of ziftomenib in NPM1-mutant AML enrollment exceeding initial projections; 85-patient target.
Updated Phase 1 ziftomenib data to be presented at EHA June 2023; 6/20 NPM1-mutant patients achieved CR at RP2D.
FDA cleared IND for KO-2806, a next-generation FTI; FIT-001 Phase 1 trial expected to dose first patients H2 2023.
First combination study KOMET-007 (ziftomenib + standards of care) to dose first patients in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported first quarter ended March 31, 2023 results: net income $34.1 million.

Period: first quarter ended March 31, 2023
Net income: $34.1 million
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $34.1 million

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.